Replies to post #410 on Oxford BioMedica PLC (OXBDF)

[georgejjl]

Novartis says U.S. regulator grants speedy review of CAR-T cell therapy

http://www.reuters.com/article/us-novartis-cancer-filing-idUSKBN1710II

CTL019 will likely cost hundreds of thousands of dollars per patient if approved, and Novartis counts it among drugs it believes will eventually exceed $1 billion in annual sales.

Good luck and GOD bless,

George